Study design
nausea, dilated colon, vomiting, colon cancer, obstructive left-sided colon cancer, abdominal distension
COLON CANCER, COLON TUMOR
The COMPASS trial is a multicenter, randomized, open-label study that will be conducted across 26 university hospitals and 40 academic hospitals in Germany. The trial was designed to show the superiority in regard to 120-day postoperative mortality among patients subjected to a two-stage bridge-to-surgery (BTS) procedure, as opposed to those undergoing a single-stage emergency resection (ER) for the management of obstructive left-sided colon cancer. Inclusion criteria involve patients presenting with symptoms of obstruction (abdominal distension, nausea, and/or vomiting) and having a left-sided colon tumor suspected of being colon cancer. Radiological assessments, including X-ray or a CT scan, must demonstrate a dilated colon with or without dilatation of the small intestine. Additionally, a high-grade suspicion of colon cancer should be identified on CT or endoscopy during the preoperative examination. Please refer to Fig. Flowchart of the trial scheme